Last reviewed · How we verify
NCT07128563
Piriform Cortex Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis
NA trial testing piriform cortex-DBS in Epilepsy, Drug Resistant in 5 participants. Not yet recruiting.
1 September 2026
Quick facts
| Lead sponsor | Xuanwu Hospital, Beijing |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 10 September 2025 |
| Primary completion | 1 September 2026 |
| Estimated completion | 1 August 2027 |
Drugs / interventions tested
- piriform cortex-DBS
Conditions studied
- Epilepsy, Drug Resistant — all drugs for Epilepsy, Drug Resistant →
Sponsor
Xuanwu Hospital, Beijing
Who can join
Adults 14 to 65, any sex, with Epilepsy, Drug Resistant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of Piriform cortex as adjunctive therapy for reducing the frequency of seizures in drug-resistant temporal lobe epilepsy with bilateral hippocampal sclerosis
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07128563
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epilepsy, Drug Resistant
Currently open trials in the same condition.
- NCT06719791 — Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE) · EARLY_PHASE1 · recruiting
- NCT06436547 — Subiculum Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis(SESTB) · NA · active not recruiting
- NCT06248333 — Subthalamic Nucleus Electrical Stimulation for Drug-resistant Focal Motor Epilepsy · NA · recruiting
Other Xuanwu Hospital, Beijing trials
Trials by the same sponsor.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
- NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
- NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
- NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07128563 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
- Last refreshed: 19 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07128563.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing